NICE says no to three colorectal cancer drugs
This article was originally published in Scrip
Executive Summary
Roche, Merck Serono and Amgen have been informed by the National Institute for Health and Clinical Excellence (NICE), the health technology assessment agency of England and Wales, that it is unlikely to recommend use by the National Health Service of their drugs to treat patients with metastatic colorectal cancer that has progressed after first line chemotherapy.